Ovation Science Inc. is a Canadian company that specializes in sub-licensing the patented drug delivery technology, Invisicare. The company has been in operation for several years and has gained recognition for its innovative drug delivery system. Invisicare is a unique technology that allows drugs to be delivered through the skin without causing irritation or discomfort to the patient.
The company has been listed on the Canadian stock exchange for a while. However, recent developments have led to the company’s decision to delist from the exchange. There are several reasons why the company has decided to delist from the exchange.
One of the primary reasons is the high cost of maintaining a listing on the stock exchange. As a publicly listed company, Ovation Science Inc. is required to comply with various regulations and reporting requirements. These requirements can be costly and time-consuming, especially for a small company like Ovation Science Inc.
Another reason for the delisting is the company’s desire to focus on its core business operations. Ovation Science Inc. believes that delisting from the stock exchange will allow it to focus more on developing and licensing its Invisicare technology. The company plans to use the funds saved from delisting to invest in research and development and expand its licensing opportunities.
Despite the delisting, Ovation Science Inc. remains optimistic about its future prospects. The company has a strong portfolio of patented drugs and partnerships with several pharmaceutical companies. Additionally, the demand for drug delivery technologies continues to increase, providing ample opportunities for the company to grow its business.
Ovation Science Inc. is a Canadian company that has gained recognition for its innovative drug delivery technology, Invisicare. The company has decided to delist from the Canadian stock exchange to focus on its core business operations and reduce costs. Despite the delisting, the company remains optimistic about its future prospects and plans to invest in research and development to expand its licensing opportunities.